One word we myeloma patients cannot wait to hear? You’re cured. With all the new innovative medications, combinations and treatment options, when can we start using that word? And how far are we away from curing myeloma? Myeloma survivor and advocate, Jack Aiello, asks these questions via Patient Power of Dr. Noopur Raje, Dr. Faith Davies and [...]
How Close Are We To A Cure For Myeloma? Patient Power Responds
↧
↧
Weds, Mar 16 & 23: Lifetime to Air Show About Multiple Myeloma
We wanted to make you aware of an upcoming multiple myeloma program on Lifetime’s Access Health. On Wednesday, March 16, 2016, the nationally syndicated program, Access Health TV (www.accesshealth.tv), will air a segment on one of their programs that will focus on Multiple Myeloma, providing an overview of the disease and treatment challenges. Featured in this broadcast [...]
↧
Why Multiple Myeloma Clinical Trials do NOT Accrue Patients
BY JIM OMEL Essentially every advancement in myeloma therapy has occurred because a clinical trial has proven the value of a better drug or treatment approach. Without clinical trials, we would not have Revlimid, Velcade, Kyprolis, pomalidomide, Ninlaro, daratumumab, elotuzumab, and on and on…. None of them! Without clincial studies we will never get exciting [...]
↧
CURE Reports – A New Lease on Life: Treatments Are Extending Life Expectancies for Myeloma Patients
Four new drugs, and novel treatment combinations, are further extending life expectancy for patients with multiple myeloma. CURE magazine has recently published an informative and hopeful article about how myeloma treatments are extended life and quality of life more than ever. The article can be read in its entirety by clicking here. Highlights include the [...]
↧
STUDY: Two-Drug Combo of Bortezomib + Oral Prednisone is Best for Frail Myeloma Patients
A two-drug combination with subcutaneous bortezomib and oral prednisone followed by maintenance therapy should be the preferred treatment for frail patients with multiple myeloma, a study published in the journal Leukemia has shown. For the phase 2 trial, researchers in Italy sought to evaluate three low-dose intensity subcutaneous bortezomib-based treatments in patients 75 years of [...]
↧
↧
Myeloma Crowd’s Jenny Ahlstrom Receives Myeloma Hero Award From Cure Magazine at Miami Event
Cure Media Group, the nation’s leading digital and print media enterprise focused on cancer patients, officially named eight recipients of the first annual Multiple Myeloma Heroes Awards to honor individuals making heroic contributions in the field of multiple myeloma or in the lives of patients with multiple myeloma. Nominated by patients, caregivers and colleagues, the [...]
↧
Janssen Inititiates Studies Evaluating Two Monoclonal Antibodies Together: Daratumumab and Atezolizum
Janssen and Genentech will enter clinical collaboration to assess dual monoclonal antibody combination therapy Janssen and Genentech are initiating two studies to determine the safety and tolerability of daratumumab (DARZALEX®) in combination with atezolizumab, an investigational monoclonal antibody. Janssen will sponsor a Phase 1b, open-label, multi-center clinical trial that will investigate the potential of daratumumab [...]
↧
Combo of Velcade, Thalidomide & Dex is Preferred Treatment for Myeloma Patients Preparing For Stem Cell Transplant
For myeloma patients preparing for an auto stem cell transplant (SCT), a new study published in the journal Blood shows that the combo of Velcade + thalidomide + dex (VTD) is more effective than Velcade + cyclophosphamide + dex (VCD). VTD and VCD have both demonstrated high response rates and are two of the most commonly [...]
↧
Patient Power: Creating SparkCures– A Site That Makes Finding a Myeloma Clinical Trial Easy-Peasy
Medical correspondent for Patient Power, Carol Preston, interviews the creator of SparkCures, Brian McMahon. Getting into a clinical trial is not as easy as one might think (or hope). In fact, it can mean sifting through sometimes thousands of clinical trial, trying to decipher what the summaries mean, and if the information is even up-to-date. [...]
↧
↧
Ready to Learn More About Myeloma From the Best Doctors Out There? Here’s Your Chance! We’re Hosting A Series Of Round Tables on High-Risk Disease. Salt Lake City Goes First on May 7, Discount Rates Available
The Myeloma Crowd is pleased to announce a new program to help patients and caregivers make better decisions and plans about treatment: Myeloma Crowd Round Tables on High-Risk Disease. These will be day-long patient education meetings featuring top myeloma experts. They will be held in cities throughout the United States—six are planned in 2016—and focus [...]
↧
Refractory Myeloma? PomCyDex May Be an Effective Oral Option
Pomalidomide plus cyclophosphamide and dexamethasone (PomCyDex) resulted in a higher overall response rate as compared with pomalidomide plus low-dose dexamethasone (PomDex) in patients with refractory multiple myeloma, a study published in the journal Blood has shown. Because PomDex is a standard treatment for patients refractory to Revlimid (lenalidomide) who have received three or more prior [...]
↧
Controlling Inflammation and Myeloma…The Nerve!
BY ERIC HANSEN Doctors are fully aware that inflammation, at the right level, helps our bodies heal from infection and injury. It’s a good and necessary thing that brings to bear our immune systems, and causes extra blood flow to the area affected along with more oxygen and nutrients to speed up healing. But too [...]
↧
Investigational Drug Aplidin Looks Promising for Treating Refractory Myeloma
More hopeful news in myeloma treatment with the advancement of PharmaMed‘s drug Aplidin® (plitidepsin) for refractory disease. The company is located in Madrid. Aplidin has received orphan drug designation by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). It is expected to be available in Australia, Southeast Asia 2018. No word yet [...]
↧
↧
Minimal Residual Disease (MRD) May Lead To Better Myeloma Treatment
In myeloma, testing for measurable residual disease (MRD) after a stem cell transplant (SCT) is mainly done in research and clinical trials. But that is getting set to change and may soon become common for the standard patient. And as doctors discover which of their patients achieve a stringent complete remission after transplant, should those that do undergo maintenance therapy? Over [...]
↧
NCCN Announces Unprecedented Myeloma Guidelines
BY GREG BROZEIT The National Comprehensive Cancer Network (NCCN), an expert panel that develops standard-of-care guidelines for practicing physicians, announced unprecedented recommendations for the treatment of myeloma. Dr. Ken Anderson, chair of the NCCN myeloma panel, told Medscape Medical News that certain patients with smoldering myeloma who “do not have the so-called CRAB features” would [...]
↧
Myeloma Crowd TV Episode 2: Myeloma Vaccines
Immunotherapy is becoming an integrated part of myeloma treatment and one important class of immunotherapy is vaccines. While we typically think of vaccines as preventing disease, these myeloma vaccines are intended to eliminate disease. In this episode, we explore vaccines that are working to perform different functions: prevent myeloma from progressing for smoldering patients, eliminate [...]
↧
Patient Power: Progress in Myeloma Care Through Combo Therapies
Are you refractory to some of the existing myeloma medications? Are you a relapsed patient? Dr. John Burke, Dr. Faith Davies and Dr. Noopur Raje along with patient advocate, Jack Aiello. For Patient Power, they discuss staying on maintenance treatment until progression in order to deepen response and achieve minimal residual disease (MRD) negativity, creative [...]
↧
↧
Wall Street Journal: Simple Tools Helps Myeloma Patients Fight Side Effects
Read the full article by Lucette Lagnado in the Wall Street Journal A recent study by assistant professor of oncological sciences at Mt. Sinai (also with the University of Reykjavik in Iceland), Dr. Heiddis Valdimarsdottir, shows that using a simple bright white light helped ease both fatigue and depression for myeloma patients. After Wanda Cwiecek [...]
↧
Oncology Clinical Pathways….What Patients Should Know
BY JIM OMEL In myeloma we have a multitude of potential treatments for each phase of our disease, and have thankfully now come far beyond the days of Melphalan and Prednisone. How do doctors decide which treatment course to suggest for us? Our general state of health, lab values, aggressiveness of disease, patient preferences, and [...]
↧
Multiple Myeloma Survival Improved To 5 Years! Yeah!!! And My Future Survival Prediction For the Next Two Years.
If you are a myeloma patient, you have to love this news. When I was diagnosed there was little data available, but I do remember a Mayo publication which said the average life expectancy was 33 months and had not changed in a decade. The new patients can now look at the new data represented [...]
↧
More Pages to Explore .....
